Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 887 / https://doi.org/10.3332/ecancer.2018.887

Case Report

Palliative splenic irradiation for symptomatic splenomegaly in non-Hodgkin lymphoma

Introduction and aims: Splenic marginal zone lymphoma, an uncommon subtype of non-Hodgkin lymphoma (NHL), is usually present with symptomatic splenomegaly. Although splenectomy has long been considered the first-line therapy in symptomatic or cytopenic patients, it can lead to significant morbidity and mortality. Splenic irradiation is an option for patients who have a poor response to systemic therapy and/or are not surgical candidates. In this paper, we present a case report of a patient who received splenic radiotherapy for symptomatic splenomegaly.

Methods: An 85-year-old Caucasian man with a 4 year history of low-grade NHL presented with progressive pancytopenia, significant weight loss and symptomatic splenomegaly (abdominal discomfort, sense of fullness and limitation of mobility due to spleen size). The patient refused splenectomy and, in December 2017, was referred to palliative splenic radiotherapy. He was initially treated with five fractions of one Grey (Gy) in order to evaluate clinical and haematology response. After that, 1.5 Gy daily, 5 days a week for 3 weeks. 3D conformal radiotherapy, multiple fields and mixed energy (6 and 15 Mv) were used.

Results: Radiotherapy allowed significant splenic reduction to almost half the size, resolving abdominal discomfort and improving quality of life. There was no decline of haemoglobin, leukocytes and platelet counts; in fact, there was a marginal increase.

Conclusion: Palliative splenic irradiation was well tolerated confirming that it is a safe treatment option for palliation of symptomatic splenomegaly. Thereby, splenic irradiation should be strongly considered in the management of symptomatic splenomegaly, for selected patients who are refractory to or unsuitable for other options or when the patient refuses other treatments.

Keywords: Palliative splenic irradiation for symptomatic splenomegaly in non-Hodgkin lymphoma

Loading Article Metrics ... Please wait

Related articles

Review: Conservative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women

Abstract | Full Article | PDF Published: 17 Jan 2019 / https://doi.org/10.3332/ecancer.2019.892

Research: Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer

Abstract | Full Article | PDF Published: 15 Jan 2019 / https://doi.org/10.3332/ecancer.2019.891

Research: Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status

Abstract | Full Article | PDF Published: 08 Jan 2019 / https://doi.org/10.3332/ecancer.2019.890

Research: The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B

Abstract | Full Article | PDF Published: 21 Dec 2018 / https://doi.org/10.3332/ecancer.2018.889

Review: Spontaneous testicular tumor regression: case report and historical review

Abstract | Full Article | PDF | Spanish Published: 18 Dec 2018 / https://doi.org/10.3332/ecancer.2018.888



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation